이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Abbott Laboratories 미래 성장

Future 기준 확인 2/6

Abbott Laboratories (는) 각각 연간 11.3% 및 6.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 11.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 21.4% 로 예상됩니다.

주요 정보

11.3%

수익 성장률

11.3%

EPS 성장률

Medical Equipment 수익 성장	16.6%
매출 성장률	6.3%
향후 자기자본 수익률	21.4%
애널리스트 커버리지	Good
마지막 업데이트	17 Jun 2024

최근 미래 성장 업데이트

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Jan 26

Recent updates

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Jun 18

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Jan 26

Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King

Dec 28

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Dec 27

Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio

Dec 03

Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?

Nov 29

Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market

Nov 26

Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?

Nov 01

Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up

Oct 24

Abbott: A Diversified Health Care Company With Strong Underlying Growth

Oct 20

Abbott Laboratories Triumphs Over Challenges: A Tale Of Resilience

Sep 29

Abbott Laboratories' (NYSE:ABT) Intrinsic Value Is Potentially 33% Above Its Share Price

Sep 26

Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income

Sep 17

We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt

Aug 13

Abbott: This Dividend King Is Ready For Takeoff

Jul 31

수익 및 매출 성장 예측

NYSE:ABT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	47,978	7,952	8,963	10,927	20
12/31/2025	44,732	7,167	7,974	9,975	23
12/31/2024	41,724	5,984	10,469	11,488	21
3/31/2024	40,326	5,608	4,923	7,143	N/A
12/31/2023	40,109	5,701	5,059	7,261	N/A
9/30/2023	39,959	5,148	4,492	6,549	N/A
6/30/2023	40,226	5,146	5,488	7,452	N/A
3/31/2023	41,505	5,785	6,823	8,659	N/A
12/31/2022	43,653	6,905	7,804	9,581	N/A
9/30/2022	45,030	7,857	8,541	10,322	N/A
6/30/2022	45,548	8,520	8,468	10,243	N/A
3/31/2022	44,514	7,695	8,152	9,961	N/A
12/31/2021	43,075	7,042	8,648	10,533	N/A
9/30/2021	42,308	7,208	9,314	11,264	N/A
6/30/2021	40,233	6,343	8,644	10,629	N/A
3/31/2021	37,338	5,693	7,609	9,823	N/A
12/31/2020	34,608	4,449	5,724	7,901	N/A
9/30/2020	32,221	3,346	4,587	6,519	N/A
6/30/2020	31,444	3,073	4,564	6,401	N/A
3/31/2020	32,095	3,539	4,476	6,139	N/A
12/31/2019	31,904	3,666	4,498	6,136	N/A
9/30/2019	31,355	3,272	3,814	5,485	N/A
6/30/2019	30,935	2,867	4,096	5,720	N/A
3/31/2019	30,723	2,582	4,450	5,904	N/A
12/31/2018	30,578	2,319	4,906	6,300	N/A
9/30/2018	30,402	802	4,903	6,175	N/A
6/30/2018	29,575	812	4,816	5,997	N/A
3/31/2018	28,445	365	4,966	6,104	N/A
12/31/2017	27,390	344	N/A	5,570	N/A
9/30/2017	25,134	1,971	N/A	5,100	N/A
6/30/2017	23,607	1,055	N/A	4,312	N/A
3/31/2017	22,303	1,384	N/A	3,870	N/A
12/31/2016	20,853	1,056	N/A	3,203	N/A
9/30/2016	20,708	989	N/A	2,861	N/A
6/30/2016	20,556	1,939	N/A	2,839	N/A
3/31/2016	20,393	2,124	N/A	2,871	N/A
12/31/2015	20,405	2,586	N/A	2,966	N/A
9/30/2015	20,573	2,523	N/A	3,376	N/A
6/30/2015	20,502	2,365	N/A	3,382	N/A
3/31/2015	20,389	2,004	N/A	3,341	N/A
12/31/2014	20,247	1,710	N/A	3,675	N/A
9/30/2014	19,905	1,560	N/A	4,062	N/A
6/30/2014	19,651	1,762	N/A	3,383	N/A
3/31/2014	19,034	1,654	N/A	3,200	N/A
12/31/2013	19,657	1,970	N/A	3,324	N/A
9/30/2013	20,275	961	N/A	3,202	N/A
6/30/2013	20,715	648	N/A	6,199	N/A

애널리스트 미래 성장 예측

수입 대 저축률: ABT 의 연간 예상 수익 증가율( 11.3% )이 saving rate( 2.4% 보다 높습니다. ).

수익 vs 시장: ABT 의 연간 수익( 11.3% ) US 시장( 14.9% 보다 느리게 성장할 것으로 예상됩니다. 14.9% 연간).

고성장 수익: ABT 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: ABT 의 수익(연간 6.3% ) US 시장( 8.7% 보다 느리게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: ABT 의 수익(연간 6.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: ABT 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 21.4 %)

Abbott Laboratories 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Recent updates

Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

First quarter dividend of US$0.55 announced

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024

Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Why I Agree With Wall Street On This One

Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock

Executive Vice President of Finance notifies of intention to sell stock

New minor risk - Insider selling

Insider recently sold US$2.4m worth of stock

First quarter 2024 earnings: EPS exceeds analyst expectations

First quarter 2024 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Upcoming dividend of US$0.55 per share

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now

Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly

Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024

Fourth quarter dividend of US$0.55 announced

Now 20% overvalued after recent price rise

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

Insider exercised options and sold US$2.6m worth of stock

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

The King Is Back: Abbott Laboratories' Path To >11% Annual Returns

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Full year 2023 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Insider notifies of intention to sell stock

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio

Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?

Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market

Abbott Announces New Late-Breaking Data That Show Advanced Heart Failure Patients Living with its HeartMate 3 Heart Pump

Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes

Abbott Laboratories Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Independent Director recently sold US$4.7m worth of stock

Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?

Independent Director notifies of intention to sell stock

Abbott Announces Late-Breaking Data from the LIFE-BTK Clinical Trial Evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up

Abbott: A Diversified Health Care Company With Strong Underlying Growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Now 20% undervalued after recent price drop

Upcoming dividend of US$0.51 per share at 2.1% yield

Abbott Laboratories Triumphs Over Challenges: A Tale Of Resilience

Abbott Laboratories to Report Q3, 2023 Results on Oct 18, 2023

Abbott Laboratories' (NYSE:ABT) Intrinsic Value Is Potentially 33% Above Its Share Price

Abbott Laboratories (NYSE:ABT) acquired Bigfoot Biomedical, Inc..

Abbott Declares Quarterly Dividend, Payable on November 15, 2023

Canadian First - Abbott's Tactiflex™ Ablation Catheter Used to Treat Afib

Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income

Abbott Laboratories (NYSE:ABT) entered into definitive agreement to acquire Bigfoot Biomedical, Inc.

Now 20% undervalued after recent price drop

We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt

Insider notifies of intention to sell stock

Abbott: This Dividend King Is Ready For Takeoff